SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology
Alessandra Greco(St. Catherine University), Fabrizio Oliva(Associazione Nazionale Medici Cardiologi Ospedalieri), Attilio Iacovoni(Ospedale Papa Giovanni XXIII), Luigi Tarantini(Santa Maria Nuova Hospital), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Furio Colivicchi(Ospedale San Filippo Neri), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Andrea Tedeschi(Guglielmo da Saliceto Hospital), Marco Corda(Azienda di Rilievo Nazionale ed Alta Specializzazione), Maria Laura Canale(Ospedale Versilia), Alessandro Navazio(Presidio Ospedaliero), Marzia De Biasio, Massimo Grimaldi(Ospedale Generale Regionale Francesco Miulli)
Cited by 20
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108